AU657866B2 - Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate and the production of the same - Google Patents

Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate and the production of the same

Info

Publication number
AU657866B2
AU657866B2 AU44227/93A AU4422793A AU657866B2 AU 657866 B2 AU657866 B2 AU 657866B2 AU 44227/93 A AU44227/93 A AU 44227/93A AU 4422793 A AU4422793 A AU 4422793A AU 657866 B2 AU657866 B2 AU 657866B2
Authority
AU
Australia
Prior art keywords
production
crystalline hydrate
triazolylthiomethylthio
same
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU44227/93A
Other languages
English (en)
Other versions
AU4422793A (en
Inventor
Yutaka Ide
Hisanori Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU4422793A publication Critical patent/AU4422793A/en
Application granted granted Critical
Publication of AU657866B2 publication Critical patent/AU657866B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU44227/93A 1992-07-31 1993-07-28 Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate and the production of the same Ceased AU657866B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4-204965 1992-07-31
JP20496592 1992-07-31

Publications (2)

Publication Number Publication Date
AU4422793A AU4422793A (en) 1994-02-03
AU657866B2 true AU657866B2 (en) 1995-03-23

Family

ID=16499234

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44227/93A Ceased AU657866B2 (en) 1992-07-31 1993-07-28 Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate and the production of the same

Country Status (23)

Country Link
US (1) US5407929A (ref)
EP (1) EP0581552B1 (ref)
KR (1) KR100245938B1 (ref)
CN (1) CN1037683C (ref)
AT (1) ATE165360T1 (ref)
AU (1) AU657866B2 (ref)
BR (1) BR9303235A (ref)
CA (1) CA2101502A1 (ref)
DE (1) DE69318077T2 (ref)
ES (1) ES2115725T3 (ref)
FI (1) FI933391L (ref)
GR (1) GR3026699T3 (ref)
HU (1) HU219637B (ref)
IL (1) IL106516A (ref)
MX (1) MX9304611A (ref)
NO (1) NO303734B1 (ref)
NZ (1) NZ248285A (ref)
PH (1) PH30109A (ref)
PL (2) PL172835B1 (ref)
RU (1) RU2118959C1 (ref)
TW (1) TW307769B (ref)
UA (1) UA37181C2 (ref)
ZA (1) ZA935529B (ref)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05643B1 (et) * 2001-02-24 2013-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
CN101219992B (zh) 2003-02-12 2011-08-31 日产化学工业株式会社 匹伐他汀钙的晶形
JP5230934B2 (ja) 2003-03-27 2013-07-10 バジリア ファルマスーチカ アーゲー 結晶形態のセファロスポリン
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX370599B (es) * 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (es) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co Un procedimiento para preparar nuevos compuestos de cefem
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
PH30109A (en) 1996-12-27
HUT68602A (en) 1995-06-28
MX9304611A (es) 1994-02-28
CN1037683C (zh) 1998-03-11
UA37181C2 (uk) 2001-05-15
IL106516A0 (en) 1993-11-15
GR3026699T3 (en) 1998-07-31
FI933391A0 (fi) 1993-07-29
NO303734B1 (no) 1998-08-24
AU4422793A (en) 1994-02-03
ATE165360T1 (de) 1998-05-15
NZ248285A (en) 1994-07-26
HU9302194D0 (en) 1993-10-28
TW307769B (ref) 1997-06-11
FI933391A7 (fi) 1994-02-01
ES2115725T3 (es) 1998-07-01
IL106516A (en) 1998-06-15
EP0581552A3 (en) 1994-06-01
BR9303235A (pt) 1994-03-01
ZA935529B (en) 1994-02-24
NO932745D0 (no) 1993-07-30
DE69318077T2 (de) 1998-10-29
RU2118959C1 (ru) 1998-09-20
EP0581552B1 (en) 1998-04-22
FI933391L (fi) 1994-02-01
CA2101502A1 (en) 1994-02-01
US5407929A (en) 1995-04-18
PL172830B1 (pl) 1997-12-31
KR940005636A (ko) 1994-03-22
NO932745L (no) 1994-02-01
CN1089948A (zh) 1994-07-27
PL172835B1 (pl) 1997-12-31
DE69318077D1 (de) 1998-05-28
KR100245938B1 (ko) 2000-04-01
EP0581552A2 (en) 1994-02-02
PL299870A1 (en) 1994-02-07
HU219637B (hu) 2001-06-28

Similar Documents

Publication Publication Date Title
AU4422793A (en) Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate and the production of the same
AU616838B2 (en) N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro- 2h-benzopyran or dihydrobenzodioxin)carboxamide derivatives
AU6787690A (en) Amino acid derivatives
AU4236889A (en) Imidazoline derivative and preparation thereof
YU54189A (en) Process for obtaining cephem derivatives and midproducts for the same
MY104937A (en) Cephalosporin derivatives and processes for their preparation
IL91001A0 (en) N-alkyl derivatives of antibiotic bu-3608 complex and pharmaceutical compositions containing them
EP0342423A3 (en) Heteroaroylhydrazide derivatives of monocyclic beta-lactam antibiotics
EP0416810A3 (en) Cephalosporin compounds, process for their preparation, pharmaceutical compositions and intermediates
AU6210690A (en) 3-pyridinium derivatives of ceph-3-em
AU6496886A (en) Cephalosporin derivatives and a process for their preparation
HUT53654A (en) Process for producing cefemcarboxylic acid compounds and pharmaceutical compositions comprising such compounds
AU6059094A (en) Active compound from a sponge
AU2776389A (en) Beta-lactam antibiotics, processes for their preparation and their use as and in medicaments
EP0390099A3 (de) Polare Cephalosporinderivate und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired